Will try to supply more jabs of Covid vaccine to UK later: Serum Institute

Last month, SII CEO Adar Poonawalla had urged other countries to be patient

AstraZeneca
Photo: Reuters
Press Trust of India New Delhi
2 min read Last Updated : Mar 19 2021 | 3:04 PM IST

Serum Institute of India (SII) has said it will try to supply more doses of Oxford-AstraZeneca COVID-19 vaccine to the United Kingdom later, based on thecurrent situation and requirement for the government immunisation programme in India.

The UK's National Health Service has warned of a significant reduction in weekly supplies of vaccines to protect against COVID-19 by the end of this month.

When contacted, a spokesperson for SII said, "Five million doses had been delivered a few weeks ago to the UK and we will try tosupply more later, based on the current situation and requirement for the government immunisation programme in India".

Last month, SII CEO Adar Poonawalla had urged other countries to be patient as they wait for the supplies of COVID-19 vaccine, Covishield, as the company has been directed to prioritise the needs of India.

Apart from making efforts to meet the requirements of India, the vaccine major is also trying its best to balance the needs of the rest of the world, he had said.

"Dear countries and governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best", Poonawalla had said in a tweet.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusSerum Institute of IndiaCoronavirus Vaccine

First Published: Mar 19 2021 | 3:01 PM IST

Next Story